Hepatic Encephalopathy Market

Market Overview:

The 7 major hepatic encephalopathy markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.9 Billion by 2034, exhibiting a growth rate (CAGR) of 5.1% during 2024-2034.

The hepatic encephalopathy market has been comprehensively analyzed in IMARC's new report titled "Hepatic Encephalopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatic encephalopathy is a neurological condition that occurs as a result of liver dysfunction or failure. The liver plays a substantial role in removing waste products from the blood, and when it becomes impaired, these toxins can accumulate in the bloodstream and affect the brain. The most common indications associated with this disorder include irritability, mood swings, agitation, confusion, depression, memory loss, disorientation, sleep disturbances, slurred speech, poor coordination between movements, tremors, muscle stiffness, a sweet, musty odor on the breath, etc. Individuals suffering from the ailment may also experience yellowing of the eyes and skin due to the liver's impaired ability to process bilirubin. Hepatic encephalopathy is usually diagnosed based on clinical symptoms, neurological examination findings, and laboratory tests that show elevated ammonia levels in the blood. The healthcare professional may also perform several diagnostic procedures, like ultrasounds, computed tomography (CT) scans, magnetic resonance imaging, etc., to assess the structure and function of the liver as well as detect any irregularities that may be contributing to the underlying indications.
 

The increasing cases of liver tissue scarring due to chronic hepatitis B or C infection, excessive alcohol consumption, genetic and metabolic disorders, etc., are primarily driving the hepatic encephalopathy market. In addition to this, the rising incidences of portal hypertension, which causes blood to bypass the liver, leading to the accumulation of toxic substances in the bloodstream that can affect brain function, are creating a positive outlook for the market. Moreover, the widespread adoption of effective antibiotics, such as neomycin and rifaximin, to treat recurrent disease conditions is further acting as another significant growth-inducing factor. These therapeutic agents work by selectively suppressing the spread of harmful bacteria in the gut while preserving beneficial gut flora to alleviate the symptoms of the illness. Apart from this, the escalating application of ornithine phenylacetate therapy, since it stimulates the synthesis of glutamine in muscle tissue to aid in the removal of ammonia via alternative pathways, thereby stabilizing cognitive function and improving mental status in patients, is expected to drive the hepatic encephalopathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the hepatic encephalopathy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hepatic encephalopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatic encephalopathy market in any manner.

Recent Developments:

• In November 2023, Vedanta Biosciences released the details of a late-breaker poster presentation detailing the findings of an investigator-sponsored, randomized, placebo-controlled Phase 2a study of VE303 as a potential therapy for hepatic encephalopathy. The study's topline results indicated that VE303 had an acceptable overall safety and tolerability profile.

Key Highlights:

• Hepatic encephalopathy is a frequent neuropsychiatric consequence of both acute and chronic liver disorders.
• At any given time, around 100,000 individuals suffer from hepatic encephalopathy.
• Up to 50% of people with cirrhosis will encounter a hepatic encephalopathy episode throughout their lifetime.
• Hepatic encephalopathy affects around 202,000 persons in the United States.
• After a diagnosis of hepatic encephalopathy, the median survival time for those with cirrhosis is lowered to two years, and one year for those over 65.

Drugs:

XIFAXAN (rifaximin) 550 mg tablets are prescribed to reduce the risk of overt hepatic encephalopathy recurrence in adults. XIFAXAN is an antibiotic that does not impact the entire body but inhibits bacterial growth in the stomach. These microorganisms are considered to be associated with symptoms of overt hepatic encephalopathy.

Ornithine phenylacetate is an effective ammonia scavenger with prospective use in the treatment of hepatic encephalopathy.  It is delivered by infusing a solution comprising equimolar quantities of ornithine and phenylacetic acid, which promote ammonia elimination via interconnected amino acid metabolic pathways.

VE303 is a drug being developed by Vedanta Biosciences to treat hepatic encephalopathy. VE303 is an orally delivered, rationally designed, and specified bacterial consortium therapeutic candidate.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hepatic encephalopathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hepatic encephalopathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hepatic encephalopathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hepatic encephalopathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the hepatic encephalopathy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the hepatic encephalopathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of hepatic encephalopathy across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of hepatic encephalopathy by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of hepatic encephalopathy by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with hepatic encephalopathy across the seven major markets?
• What is the size of the hepatic encephalopathy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of hepatic encephalopathy?
• What will be the growth rate of patients across the seven major markets?
   

Hepatic Encephalopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hepatic encephalopathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatic encephalopathy market?
• What are the key regulatory events related to the hepatic encephalopathy market?
• What is the structure of clinical trial landscape by status related to the hepatic encephalopathy market?
• What is the structure of clinical trial landscape by phase related to the hepatic encephalopathy market?
• What is the structure of clinical trial landscape by route of administration related to the hepatic encephalopathy market?